Skip to Content

Fasenra Approval History

FDA Approved: Yes (First approved November 14, 2017)
Brand name: Fasenra
Generic name: benralizumab
Dosage form: Injection
Company: AstraZeneca
Treatment for: Asthma

Fasenra (benralizumab) is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody indicated for the treatment of patients with severe eosinophilic asthma.

Development History and FDA Approval Process for Fasenra

DateArticle
Nov 14, 2017Approval FDA Approves Fasenra (benralizumab) for Severe Eosinophilic Asthma
May 22, 2017Phase III ZONDA Trial for Benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients
Sep  5, 2016Benralizumab Phase III Trials Show Positive Results in Severe Asthma
May 17, 2016AstraZeneca Announces Positive Results from Benralizumab Phase III Programme in Severe Asthma

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide